Interventions for postburn pruritus
Sarthak Sinha,Vincent A Gabriel,Rohit K Arora,Wisoo Shin,Janis Scott,Shyla K Bharadia,Myriam Verly,Waleed M Rahmani,Duncan A Nickerson,Frankie OG Fraulin,Pallab Chatterjee,Rajeev B Ahuja,Jeff A Biernaskie
DOI: https://doi.org/10.1002/14651858.cd013468.pub2
IF: 8.4
2024-06-06
Cochrane Database of Systematic Reviews
Abstract:Postburn pruritus (itch) is a common and distressing symptom experienced on healing or healed burn or donor site wounds. Topical, systemic, and physical treatments are available to control postburn pruritus; however, it remains unclear how effective these are. To assess the effects of interventions for treating postburn pruritus in any care setting. In September 2022, we searched the Cochrane Wounds Specialised Register, the Cochrane Central Register of Controlled Trials (CENTRAL), Ovid MEDLINE (including In‐Process & Other Non‐Indexed Citations), Ovid Embase, and EBSCO CINAHL Plus. We also searched clinical trials registries and scanned references of relevant publications to identify eligible trials. There were no restrictions with respect to language, publication date, or study setting. Randomised controlled trials (RCTs) that enrolled people with postburn pruritus to compare an intervention for postburn pruritus with any other intervention, placebo or sham intervention, or no intervention. We used the standard methodological procedures expected by Cochrane. We used GRADE to assess the certainty of the evidence. We included 25 RCTs assessing 21 interventions with 1166 randomised participants. These 21 interventions can be grouped into six categories: neuromodulatory agents (such as doxepin, gabapentin, pregabalin, ondansetron), topical therapies (such as CQ‐01 hydrogel, silicone gel, enalapril ointment, Provase moisturiser, beeswax and herbal oil cream), physical modalities (such as massage therapy, therapeutic touch, extracorporeal shock wave therapy, enhanced education about silicone gel sheeting), laser scar revision (pulsed dye laser, pulsed high‐intensity laser, fractional CO2 laser), electrical stimulation (transcutaneous electrical nerve stimulation, transcranial direct current stimulation), and other therapies (cetirizine/cimetidine combination, lemon balm tea). Most RCTs were conducted at academic hospitals and were at a high risk of performance, attrition, and detection bias. While 24 out of 25 included studies reported change in burn‐related pruritus, secondary outcomes such as cost‐effectiveness, pain, patient perception, wound healing, and participant health‐related quality of life were not reported or were reported incompletely. Neuromodulatory agents versus antihistamines or placebo There is low‐certainty evidence that doxepin cream may reduce burn‐related pruritus compared with oral antihistamine (mean difference (MD) ‐2.60 on a 0 to 10 visual analogue scale (VAS), 95% confidence interval (CI) ‐3.79 to ‐1.42; 2 studies, 49 participants). A change of 2 points represents a minimal clinically important difference (MCID). Due to very low‐certainty evidence, it is uncertain whether doxepin cream impacts the incidence of somnolence as an adverse event compared to oral antihistamine (risk ratio (RR) 0.64, 95% CI 0.32 to 1.25; 1 study, 24 participants). No data were reported on pain in the included study. There is low‐certainty evidence that gabapentin may reduce burn‐related pruritus compared with cetirizine (MD ‐2.40 VAS, 95% CI ‐4.14 to ‐0.66; 1 study, 40 participants). A change of 2 points represents a MCID. There is low‐certainty evidence that gabapentin reduces the incidence of somnolence compared to cetirizine (RR 0.02, 95% CI 0.00 to 0.38; 1 study, 40 participants). No data were reported on pain in the included study. There is low‐certainty evidence that pregabalin may result in a reduction in burn‐related pruritus intensity compared with cetirizine with pheniramine maleate (MD ‐0.80 VAS, 95% CI ‐1.24 to ‐0.36; 1 study, 40 participants). A change of 2 points represents a MCID. There is low‐certainty evidence that pregabalin reduces the incidence of somnolence compared to cetirizine (RR 0.04, 95% CI 0.00 to 0.69; 1 study, 40 participants). No data were reported on pain in the included study. There is moderate‐certainty evidence that ondansetron probably results in a reduction in burn‐related pruritus intensity compared with diphenhydramine (MD ‐0.76 on a 0 to 10 numeric analogue scale (NAS), 95% CI ‐1.50 to ‐0.02; 1 study, 38 participants). A change of 2 points represents a MCID. No data were reported on pain and adverse events in the included study. Topical therapies versus relevant comparators There is moderate‐certainty evidence that enalapril ointment probably decreases mean burn‐related pruritus compared with placebo control (MD ‐0.70 on a 0 to 4 scoring table for itching, 95% CI ‐1.04 to ‐0.36; 1 study, 60 participants). No data were reported on pain and adverse events in the included study. Physical modalities versus relevant comparators Compared with standard care, there is low‐certainty evidence that massage may reduce burn‐related pruritus (standardised mean difference (SMD) ‐0.86, 95% CI ‐1.45 to ‐0.27; 2 studies, 166 participants) and pain (SMD ‐1.32, 95% CI ‐1.66 to ‐0.98). These SMDs equat -Abstract Truncated-
medicine, general & internal